Category IP Law

IP-Watch Readers Save $200 On LES Spring Meeting, 14-16 May In Seattle

LES (USA & Canada) 2013 Spring Meeting
IP Matters In Every Deal
May 14-16 | Seattle, WA

Look Who's Attending the 2013 LES Spring Meeting
The LES Spring Meeting, 14-16 May in Seattle, Washington, USA is your best opportunity to learn about the latest trends in licensing and network with the industry's leading IP, licensing and business development dealmakers.    

CONNECT with your next partner, LEARN new strategies and practices, COLLABORATE with your colleagues during one of many networking sessions.

You don't want to miss out!

IP Watch readers SAVE $200! Use code IPW13 when registering.

REGISTER!

DOWNLOAD THE BROCHURE!

View the full agenda here.


 

Join this Growing List of Participants:
(This is a partial list of confirmed attendees.)

Company Title
343 Industries IP Licensing Manager
Adobe VP, IP and Litigation
Allen Institute for Brain Science General Counsel
Aruze Gaming America Executive Vice President, General Counsel
Augme Technologies Director and CEO
Autodesk VP, Legal
Battelle/Pacific Northwest National Lab Commercialization Manager
Bayer MaterialScience LLC Manager IP/Library Information Services
Bill & Melinda Gates Foundation Associate General Counsel
Boeing IP Licensing Company Business Development
Boston University Licensing Director, Life Sciences
California Technology Ventures Founding Managing Director
Caterpillar Inc. Intellectual Asset Manager
Center for Infectious Diseases Executive VP of BD and External Affairs
Cryptography Research, Inc. Director
Eli Lilly and Company VP, Corporate Business Development
Fred Hutchinson Cancer Research Center VP, Industry Relations and Clinical Research Support
HealthPartners Institute IP Marketing and Licensing Manager
hipcricket Chief Executive Officer
HP VP & Associate General Counsel
HTC Sr. Director of Legal Affairs, IP Strategy
IBM Director of IP Strategy
Integrated Diagnostics Director of IP and Contracts
Intellectual Ventures VP, Acquisitions
Jet Propulsion Laboratory & Caltech Associate Director
John Deere Manager IP Market Transactions
Joint BioEnergy Institute Director of Commercialization
Juniper Networks Inc Assistant General Counsel
Lawrence Livermore National Laboratory Business Development Executive
Lehigh University Associate Director
Lexington Technology Group, Inc. CEO
LI-COR Biosciences VP Business Development and Intellectual Property
Merck Executive Director, Corporate Licensing
Microsoft Associate General Counsel
NeoMedia Technologies CEO
Nike Corporation VP, Chief IP Counsel
Northwest Energy Angels Board Member & Angel Investor
OncoSynergy Co-Founder
Oracle Patent Counsel
Oregon Health & Science University Interim Director
Pacific Northwest National Lab Director Technology Commercialization
PhaseBio Chief Business Officer
Purdue Research Foundation, OTC Senior Project Manager
Rockwell Collins, Inc. Senior Director, Intellectual Property Management 
Rutgers University Licensing Manager
SanDisk IP Counsel
Sanrio Vice Chairman
SAS Head of Corp Development & Planning
Schlumberger Manager of IP Licensing
Seattle Genetics Chief Operating Officer
Stanford University Senior Associate
Tech Bridge International, Inc. VP & Director of Operations
Textron Inc. Intellectual Property Director
The Boston Consulting Group Senior Advisor
The University of North Carolina at Charlotte Executive Director
The University of Oklahoma Senior Director of IP & Staff Attorney
T-Mobile Senior Vice President, National Accounts
Tuxera CEO
UCSF QB3 Institute Director Industrial Alliances
Univalor, L.P. Manager, Project and Technology Portfolio
University Health Network Senior Technology and Patent Analyst
University of Arizona Office of Tech Transfer Licensing Associate
University of California - Berkeley Licensing Officer
UW Center for Commercialization Associate Director, Technology Licensing - Engineering
Ventures West Capital General Partner
Washington Research Foundation Director of Licensing
WBBA President
Weyerhaeuser Director, Technology Licensing
WMS Gaming Executive Director IP Licensing and Development


Don't Miss these Featured Sessions:

View the full agenda here.

US Supreme Court May Invalidate Gene Patents, But Create Little Change

Prior to 15 April, most experts had expected the United States Supreme Court to rule in Association for Molecular Pathology v. Myriad Genetics that genes cannot be patented. The oral argument on that date strengthened this consensus opinion, but also suggested that the court would issue a narrow decision which would allow many types of gene-related patents. Should this happen, the US would move significantly closer to other countries’ rules for gene patents, but the US would continue to have problems limiting patent rights in order to protect the public interest.

EU General Court Clears Copyright Collecting Societies Of Antitrust Charges

European copyright collecting societies are not engaged in a cartel but the European Commission was correct in finding that some of the provisions in their reciprocal representation should be barred, the EU General Court (GC) said in a 12 April ruling. The case, which pits the International Confederation of Societies and Authors (CISAC) and 24 of its members against the EC, could be appealed to the EU Court of Justice (ECJ). CISAC said the decision proves its contention that it was not engaged in a conspiracy to restrict competition, and that it has already done away with the complained-of clauses.

Separately, the ECJ has been asked to tackle several key issues in a German matter involving standards-essential patents encumbered with a fair, reasonable and non-discriminatory (FRAND) licensing agreement.

Community Right To Access Unpublished Works Trumps Moral Rights Of Heir, Argentine Court Says

In a recent decision, Ediciones de la Flor SA c. Fontanarrosa Franco s. Acción Mere Declarativa (File No. 1420/08), the Court of First Instance in Civil and Commercial Matters No. 12 of Rosario, the second largest city in Argentina, ruled that the rights of the community to access unpublished works of a deceased author are superior to the moral rights of one of his heirs to oppose such publication.